A densitometric assessment of skeletal mineral levels in prostate cancer patients treated with hormones
Kharchenko, V.P.; Kaprin, A.D.; Adzhamatov, S.R.
Voprosy Onkologii 50(5): 595-598
2004
ISSN/ISBN: 0507-3758 PMID: 15715104 Document Number: 575322
An assessment of the densitometry data on 76 patients established a progressively falling level of minerals in the skeleton as a result of treatment with hormones for prostate cancer. The basal mineral levels had been identified by means of dual-energy X-ray absorptiometry. While said changes were immediately caused by maximum androgen deprivation, tumor influence and medication contributed too.
Document emailed within 1 workday
Related Documents
Konstantynowicz, J.; Kaczmarski, M.; Piotrowska-Jastrzebska, J.; Sienkiewicz, J. 1998: Densitometric evaluation of mineral deposits in children and young people with food sensitivity who were treated by diet therapy Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 5(28): 203-207Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Wu, C.T.; Chuang, C.K.; Chou, C.C.; Chu, S.H.; Chen, H.W.; Chen, C.S.; Chiang, Y.J.; Liao, S.K. 2000: The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml Chang Gung Medical Journal 23(3): 142-148
Agarwal, M.M.; Mandal, A.K.; Khandelwal, N.; Singh, S.K. 2007: Need for measurement of bone mineral density in patients of prostate cancer before and after orchidectomy: role of quantitative computer tomography Journal of the Association of Physicians of India 55: 486-490
Incorvaia, L.; Badalamenti, G.; Rini, G.; Arcara, C.; Fricano, S.; Sferrazza, C.; Di Trapani, D.; Gebbia, N.; Leto, G. 2007: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone Anticancer Research 27(3b): 1519-1525
Tarle, M.; Kraus, O.; Trnski, D.; Reljic, A.; Ruzic, B.; Katusic, J.; Spajic, B.; Kusic, Z. 2003: Early diagnosis of prostate cancer in finasteride treated BPH patients Anticancer Research 23(1b): 693-696
Fosså, S.D.; Aass, N.; Opjordsmoen, S. 1994: Assessment of quality of life in patients with prostate cancer Seminars in Oncology 21(5): 657-661
Kuralasov, A.K.; Togaĭbaeva, Z.I.; Nurmakova, S.I.; Khan, O.G. 1986: Level of steroid and tropic pituitary hormones in the blood of patients with breast cancer treated with tamoxifen Voprosy Onkologii 32(8): 34-38
Dahmani, L.; Wagner, B.; Auzanneau, C.; Irani, J.; Doré, B. 2003: Prevalence of osteoporotic fractures in patients treated by androgen blockade for prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(1): 73-78
Erdamar, S.; Yang, G.; Harper, J.W.; Lu, X.; Kattan, M.W.; Thompson, T.C.; Wheeler, T.M. 1999: Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 12(8): 751-755
Amayo, A.; Obara, W. 2004: Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate East African Medical Journal 81(1): 22-26
Eapen, L. 1994: Long-term follow-up of patients treated by radiation therapy for clinically-localized prostate cancer Canadian Journal of Oncology 4(Suppl 1): 31-32
2015: (P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)? Oncology 29(4 Suppl. 1)
Aaltomaa, S.; Kärjä, V.; Lipponen, P.; Isotalo, T.; Kankkunen, J.P.; Talja, M.; Mokka, R. 2006: Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy Anticancer Research 26(6c): 4873-4878
Têtu, B. 1994: Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results Canadian Journal of Oncology 4(Suppl 1): 33-34; Discussion: 35-36
Lizis-Kolus, K.; Hubalewska-Dydejczyk, A.; Trofimiuk-Muldnerz, Młgorzata.; Sowa-Staszczak, A.; Kowalska, A. 2013: Assessment of 25(OH)D3, concentration levels in patients with papillary thyroid cancer compared to patients with Hashimoto's thyroiditis Przeglad Lekarski 70(11): 920-925
Osella, D.; Moschini, M.T.; Della Toffola, A.; Perino, A.; Giorgis, G.E.; Galietti, F. 1987: Assessment of IgE serum levels in lung cancer patients Panminerva Medica 29(1): 23-25
Di Silverio, F.; Gagliardi, V.; Sorcini, G.; Sciarra, F. 1976: Biosynthesis and metabolism of androgenic hormones in cancer of the prostate Investigative Urology 13(4): 286-288
Miglietta, L.; Cannobbio, L.; Boccardo, F. 1995: Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity Anticancer Research 15(6b): 2825-2828
Tarle, M. 1993: Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer Anticancer Research 13(3): 769-777